Pharmacopeia and GlaxoSmithKline Collaboration : a New Lead Compound

Jun 04, 2008 - Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that it has identified a new lead compound for advancement in its alliance with GlaxoSmithKline (NYSE: GSK), through its collaboration with the Center of Excellence for External Drug Discovery (CEEDD). This newly identified lead compound is the second from a program being evaluated as a potential treatment for respiratory disease.
As a result of this identification, Pharmacopeia received a $500,000 milestone payment from GSK... Pharmacopeia's Press Release -

Pharmacopeia , Phase 1 Clinical Trials of a potential treatment for respiratory disease

Sep 25, 2007 -Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that Schering-Plough has initiated a Phase 1 clinical trial in the United States with PS948115, a compound identified from the collaboration between the two companies. The compound is being evaluated as a potential treatment for respiratory disease... Pharmacopeia's Press Release -